| MPC | marine protein concentrate; maximum permissible concentration; mean plasma concentration; meperidine... |
|---|---|
| MBD | Marchiafava-Bignami disease; Mental Deterioration Battery; methylene blue dye; minimal brain damage;... |
| MCD | magnetic circular dichroism; mast-cell degranulation; mean cell diameter; mean of consecutive differ... |
| MPD | main pancreatic duct; maximum permissible dose; mean population doubling; membrane potential differe... |
| BA | Bachelor of Arts; backache; bacterial agglutination; basilar artery; basion; benzyladenine; best amp... |
| adrenergic blocking agent | A compound that selectively blocks or inhibits responses to sympathetic adrenergic nerve activity (sympatholytic agent) and to epinephrine, norepinephrine, and other adrenergic amines (adrenolytic agent); two distinct classes exist, alpha-and beta-adrenergic receptor blocking agent's. (05 Mar 2000) |
|---|---|
| adrenergic neuronal blocking agent | A drug that prevents the release of norepinephrine from sympathetic nerve terminals; it does not inhibit the responses of the adrenergic receptors to circulating epinephrine, norepinephrine, and other adrenergic amines. (05 Mar 2000) |
| alpha-adrenergic blocking agent | An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension. Synonym: alpha-blocker. (05 Mar 2000) |
| alpha blocking | The attenuation of the occipital alpha rhythm (8-14 Hz brain waves as seen on an electroencephalogram), produced by opening the eyes or by intense mental concentration. (05 Mar 2000) |
| antibodies, blocking | Antibodies that inhibit the reaction between antigen and other antibodies or sensitised T-lymphocytes (e.g., antibodies of the IgG class that compete with IgE antibodies for antigen, thereby blocking an allergic response). Blocking antibodies that bind tumours and prevent destruction of tumour cells by cytotoxic T-lymphocytes have also been called enhancing antibodies. (12 Dec 1998) |
| beta-adrenergic blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| blocking | 1. Obstructing; arresting of passage, conduction, or transmission. 2. In psychoanalysis, a sudden break in free association occurring when a painful subject or repressed complex is touched. 3. Sudden cessation of thoughts and speech, which may indicate the presence of a severe thought disorder or a psychosis. (05 Mar 2000) |
| blocking activity | The repression or elimination of electrical activity in the brain by the arrival of a sensory stimulus. (05 Mar 2000) |
| blocking agent | A class of drugs that inhibit (block) a biologic activity or process, such as axonal conduction or transmission, or ions across a cell membrane; frequently called "blockers." (05 Mar 2000) |
| blocking antibody | An antibody used in a reaction to prevent some other reaction taking place, for example one antibody competing with another for a cell surface receptor. See: desensitisation. (18 Nov 1997) |
| ganglionic blocking agent | An agent that impairs the passage of impulses in autonomic ganglia. (05 Mar 2000) |
| Rh blocking test | A test for nonagglutinating Rh antibodies: an Rh agglutination test is first carried out; if the test for Rh agglutinins is negative, then 1 drop of anti-Rho agglutinating serum of moderate titre is mixed with the patient's serum containing Rh-positive test cells; if after incubating for from 1 to 2 hr at 37캜 no agglutination occurs, Rho-blocking antibodies are assumed to be present in the patient's serum. (05 Mar 2000) |
| slow channel-blocking agent | calcium channel-blocking agent |
| spermatogenesis-blocking agents | Chemical substances which inhibit the process of spermatozoa formation at either the first stage, in which spermatogonia develop into spermatocytes and then into spermatids, or the second stage, in which spermatids transform into spermatozoa. (12 Dec 1998) |